ORAL ABSTRACT SESSION
Interesting to note that patients with prior immune therapy had better response than the ones who started on MEK inhibitor.
So unfortunately, not really great news for patients with NRAS mutant Melanoma:
Good overview over targeted therapy:
And again- patients with lower LDH do better-
A very nice write-up from ASCO can be found here.
Georgina V. Long, BSc, PhD, MBBS, FRACP - Presenter Disclosure